Evidence of reactive astrocytes but not peripheral immune system activation in a mouse model of Fragile X syndrome

Biochimica et Biophysica Acta - Molecular Basis of Disease

Volumn 1802, Issue 11, 2010, Pages 1006-1012

  Yuskaitis, Christopher J ^a   Beurel, Eleonore ^a   Jope, Richard S ^a  

^a UNIVERSITY OF ALABAMA AT BIRMINGHAM   (United States)

Author keywords

Astrocytes; Fragile X syndrome; Glycogen synthase kinase 3; Lithium; Macroorchidism

Indexed keywords

FRAGILE X MENTAL RETARDATION PROTEIN; GLYCOGEN SYNTHASE KINASE 3; LITHIUM CARBONATE; SERINE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; ASTROCYTE; AUTISM; BRAIN REGION; CEREBELLUM; CONTROLLED STUDY; CORPUS STRIATUM; ENZYME PHOSPHORYLATION; FRAGILE X SYNDROME; GENE FUNCTION; IMMUNE SYSTEM; IMMUNITY; IMMUNOSTIMULATION; KNOCKOUT MOUSE; MACROORCHIDISM; MALE; MOUSE; NONHUMAN; PHENOTYPE; PRIORITY JOURNAL; TREATMENT DURATION; TREATMENT OUTCOME; WILD TYPE;

ANIMALS; ASTROCYTES; BRAIN; CYTOKINES; DISEASE MODELS, ANIMAL; FEMALE; FRAGILE X MENTAL RETARDATION PROTEIN; FRAGILE X SYNDROME; GLIAL FIBRILLARY ACIDIC PROTEIN; GLYCOGEN SYNTHASE KINASE 3; IMMUNE SYSTEM; IMMUNOBLOTTING; LITHIUM CARBONATE; MALE; MICE; MICE, INBRED C57BL; MICE, KNOCKOUT; MICROGLIA; PHOSPHORYLATION; SERINE; TESTIS;

MUS;

EID: 77956650824     PISSN: 09254439     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.bbadis.2010.06.015     Document Type: Article

References (54)

1. Bear M.F., Huber K.M., Warren S.T. The mGluR theory of fragile X mental retardation. Trends Neurosci. 2004, 27:370-377.
2. Koukoui S.D., Chaudhuri A. Neuroanatomical, molecular genetic, and behavioral correlates of fragile X syndrome. Brain Res. Rev. 2007, 53:27-38.
3. Belmonte M.K., Bourgeron T. Fragile X syndrome and autism at the intersection of genetic and neural networks. Nat. Neurosci. 2006, 9:1221-1225.
4. Hagerman R.J., Ono M.Y., Hagerman P.J. Recent advances in fragile X: a model for autism and neurodegeneration. Curr. Opin. Psychiatry 2005, 18:490-496.
5. Hatton D.D., Sideris J., Skinner M., Mankowski J., Bailey D.B., Roberts J., Mirrett P. Autistic behavior in children with fragile X syndrome: prevalence, stability, and the impact of FMRP. Am. J. Med. Genet. A 2006, 140A:1804-1813.
6. Kau A.S., Tierney E., Bukelis I., Stump M.H., Kates W.R., Trescher W.H., Kaufmann W.E. Social behavior profile in young males with fragile X syndrome: characteristics and specificity. Am. J. Med. Genet. A 2004, 126A:9-17.
7. Loesch D.Z., Bui Q.M., Dissanayake C., Clifford S., Gould E., Bulhak-Paterson D., Tassone F., Taylor A.K., Hessl D., Hagerman R., Huggins R.M. Molecular and cognitive predictors of the continuum of autistic behaviours in fragile X. Neurosci. Biobehav. Rev. 2007, 31:315-326.
8. Moy S.S., Nadler J.J. Advances in behavioral genetics: mouse models of autism. Mol. Psychiatry 2008, 13:4-26.
9. Sullivan K., Hatton D., Hammer J., Sideris J., Hooper S., Ornstein P., Bailey D. ADHD symptoms in children with FXS. Am. J. Med. Genet. A 2006, 140:2275-2288.
10. Consortium T.D.-B.F.X. Fmr1 knockout mice: a model to study fragile X mental retardation. Cell 1994, 78:23-33.
11. Liu Z.H., Smith C.B. Dissociation of social and nonsocial anxiety in a mouse model of fragile X syndrome. Neurosci. Lett. 2009, 454:62-66.
12. McNaughton C.H., Moon J., Strawderman M.S., Maclean K.N., Evans J., Strupp B.J. Evidence for social anxiety and impaired social cognition in a mouse model of fragile X syndrome. Behav. Neurosci. 2008, 122:293-300.
13. Min W.W., Yuskaitis C.J., Yan Q., Sikorski C., Chen S., Jope R.S., Bauchwitz R.P. Elevated glycogen synthase kinase-3 activity in Fragile X mice: key metabolic regulator with evidence for treatment potential. Neuropharmacology 2009, 56:463-472.
14. Mines M.A., Yuskaitis C.J., King M.K., Beurel E., Jope R.S. GSK3 influences social preference and anxiety-related behaviors during social interaction in a mouse model of fragile X syndrome and autism. PLoS ONE 2010, 5:e9706.
15. Mineur Y.S., Huynh L.X., Crusio W.E. Social behavior deficits in the Fmr1 mutant mouse. Behav. Brain Res. 2006, 168:172-175.
16. Mineur Y.S., Sluyter F., de Wit S., Oostra B.A., Crusio W.E. Behavioral and neuroanatomical characterization of the Fmr1 knockout mouse. Hippocampus 2002, 12:39-46.
17. Moy S.S., Nadler J.J., Young N.B., Nonneman R.J., Grossman A.W., Murphy D.L., D'Ercole A.J., Crawley J.N., Magnuson T.R., Lauder J.M. Social approach in genetically engineered mouse lines relevant to autism. Genes Brain Behav. 2009, 8:129-142.
18. Spencer C.M., Alekseyenko O., Serysheva E., Yuva-Paylor L.A., Paylor R. Altered anxiety-related and social behaviors in the Fmr1 knockout mouse model of fragile X syndrome. Genes Brain Behav. 2005, 4:420-430.
19. Spencer C.M., Graham D.F., Yuva-Paylor L.A., Nelson D.L., Paylor R. Social behavior in Fmr1 knockout mice carrying a human FMR1 transgene. Behav. Neurosci. 2008, 122:710-715.
20. Yuskaitis C.J., Mines M.A., King M.K., Sweatt J.D., Miller C.A., Jope R.S. Lithium ameliorates altered glycogen synthase kinase-3 and behavior in a mouse model of fragile X syndrome. Biochem. Pharmacol. 2010, 79:632-646.
21. Dolen G., Osterweil E., Rao B.S., Smith G.B., Auerbach B.D., Chattarji S., Bear M.F. Correction of fragile X syndrome in mice. Neuron 2007, 56:955-962.
22. Klein P.S., Melton D.A. A molecular mechanism for the effect of lithium on development. Proc. Natl. Acad. Sci. U.S.A. 1996, 93:8455-8459.
23. Stambolic V., Ruel L., Woodgett J.R. Lithium inhibits glycogen synthase kinase-3 activity and mimics wingless signalling in intact cells. Curr. Biol. 1996, 6:1664-1668.
24. Di Filippo M., Sarchielli P., Picconi B., Calabresi P. Neuroinflammation and synaptic plasticity: theoretical basis for a novel, immune-centred, therapeutic approach to neurological disorders. Trends Pharmacol. Sci. 2008, 29:402-412.
25. Lehnardt S. Innate immunity and neuroinflammation in the CNS: the role of microglia in Toll-like receptor-mediated neuronal injury. Glia 2010, 58:253-263.
26. Bilousova T.V., Dansie L., Ngo M., Aye J., Charles J.R., Ethell D.W., Ethell I.M. Minocycline promotes dendritic spine maturation and improves behavioural performance in the fragile X mouse model. J. Med. Genet. 2009, 46:94-102.
27. Miller A.H., Maletic V., Raison C.L. Inflammation and its discontents: the role of cytokines in the pathophysiology of major depression. Biol. Psychiatry 2009, 65:732-741.
28. Ashwood P., Wills S., Van de Water J. The immune response in autism: a new frontier for autism research. J. Leukoc. Biol. 2006, 80:1-15.
29. Garbett K., Ebert P.J., Mitchell A., Lintas C., Manzi B., Mirnics K., Persico A.M. Immune transcriptome alterations in the temporal cortex of subjects with autism. Neurobiol. Dis. 2008, 30:303-311.
30. Patterson P.H. Immune involvement in schizophrenia and autism: etiology, pathology and animal models. Behav. Brain Res. 2009, 204:313-321.
31. Dong W.K., Greenough W.T. Plasticity of nonneuronal brain tissue: roles in developmental disorders. Ment. Retard. Dev. Disabil. Res. Rev. 2004, 10:85-90.
32. Pardo C.A., Vargas D.L., Zimmerman A.W. Immunity, neuroglia and neuroinflammation in autism. Int. Rev. Psychiatry 2005, 17:485-495.
33. Vargas D.L., Nascimbene C., Krishnan C., Zimmerman A.W., Pardo C.A. Neuroglial activation and neuroinflammation in the brain of patients with autism. Ann. Neurol. 2005, 57:67-81.
34. P. Ashwood, D.V. Nguyen, D. Hessl, R.J. Hagerman, F. Tassone, Plasma cytokine profiles in Fragile X subjects: is there a role for cytokines in the pathogenesis?, Brain Behav Immun 24 (2010) 898-902.
35. Frame S., Cohen P. GSK3 takes centre stage more than 20years after its discovery. Biochem. J. 2001, 359:1-16.
36. Jope R.S., Johnson G.V. The glamour and gloom of glycogen synthase kinase-3. Trends Biochem. Sci. 2004, 29:95-102.
37. Woodgett J.R. Molecular cloning and expression of glycogen synthase kinase-3/factor A. EMBO J. 1990, 9:2431-2438.
38. Beurel E., Michalek S.M., Jope R.S. Innate and adaptive immune responses regulated by glycogen synthase kinase-3 (GSK3). Trends Immunol. 2010, 31:24-31.
39. Martin M., Rehani K., Jope R.S., Michalek S.M. Toll-like receptor-mediated cytokine production is differentially regulated by glycogen synthase kinase 3. Nat. Immunol. 2005, 6:777-784.
40. Beurel E., Jope R.S. Lipopolysaccharide-induced interleukin-6 production is controlled by glycogen synthase kinase-3 and STAT3 in the brain. J. Neuroinflammation 2009, 6:9.
41. Yuskaitis C.J., Jope R.S. Glycogen synthase kinase-3 regulates microglial migration, inflammation, and inflammation-induced neurotoxicity. Cell. Signal. 2009, 21:264-273.
42. Jope R.S., Yuskaitis C.J., Beurel E. Glycogen synthase kinase-3 (GSK3): inflammation, diseases, and therapeutics. Neurochem. Res. 2007, 32:577-595.
43. Singh K., Gaur P., Prasad S. Fragile x mental retardation (Fmr-1) gene expression is down regulated in brain of mice during aging. Mol. Biol. Rep. 2007, 34:173-181.
44. Yao H.B., Shaw P.C., Wong C.C., Wan D.C. Expression of glycogen synthase kinase-3 isoforms in mouse tissues and their transcription in the brain. J. Chem. Neuroanat. 2002, 23:291-297.
45. Pacey L.K., Doering L.C. Developmental expression of FMRP in the astrocyte lineage: implications for fragile X syndrome. Glia 2007, 55:1601-1609.
46. Laurence J.A., Fatemi S.H. Glial fibrillary acidic protein is elevated in superior frontal, parietal and cerebellar cortices of autistic subjects. Cerebellum 2005, 4:206-210.
47. Doble B.W., Woodgett J.R. GSK-3: tricks of the trade for a multi-tasking kinase. J. Cell Sci. 2003, 116:1175-1186.
48. Force T., Woodgett J.R. Unique and overlapping functions of GSK-3 isoforms in cell differentiation and proliferation and cardiovascular development. J. Biol. Chem. 2009, 284:9643-9647.
49. Messing A., Brenner M. GFAP: functional implications gleaned from studies of genetically engineered mice. Glia 2003, 43:87-90.
50. Beurel E., Jope R.S. Differential regulation of STAT family members by glycogen synthase kinase-3. J. Biol. Chem. 2008, 283:21934-21944.
51. Jacobs S., Doering L.C. Astrocytes prevent abnormal neuronal development in the fragile x mouse. J. Neurosci. 2010, 30:4508-4514.
52. Berry-Kravis E., Sumis A., Hervey C., Nelson M., Porges S.W., Weng N., Weiler I.J., Greenough W.T. Open-label treatment trial of lithium to target the underlying defect in fragile X syndrome. J. Dev. Behav. Pediatr. 2008, 29:293-302.
53. McBride S.M., Choi C.H., Wang Y., Liebelt D., Braunstein E., Ferreiro D., Sehgal A., Siwicki K.K., Dockendorff T.C., Nguyen H.T., McDonald T.V., Jongens T.A. Pharmacological rescue of synaptic plasticity, courtship behavior, and mushroom body defects in a Drosophila model of fragile X syndrome. Neuron 2005, 45:753-764.
54. Jope R.S. Anti-bipolar therapy: mechanism of action of lithium. Mol. Psychiatry 1999, 4:117-128.